Inhibitors of IDH1/2 act at the interface of epigenetic and metabolic vulnerabilities and have been FDA‐approved for the treatment of IDH‐mutant glioma, cholangiocarcinoma, and myeloid malignancies. This evidence concerns the gene IDH1 and central nervous system cancer.